Cellectis SA
USUSDCellectis SA (PA:ALCLS) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 3. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- cellectis.com
- Investorite Suhted
- cellectis.com/en/investors/governance/
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Peakontor
- France, France
- Tegevjuht
- Andre Choulika
- Töötajad
- 224
- Asutatud
- 1999
- Ringluses Olevad Aktsiad
- 72.72 mln
- Vabalt Kaubeldavad Aktsiad
- 48.58 mln
- Turukapitalisatsioon
- 148.06 mln USD
- Siseringi Isikud
- 0%
- Institutsionaalsed Investorid
- 15.36%
- Tegevusala (SIC)
- Biological Products, (No Diagnostic Substances)
- Õiguslik Vorm
- QVPB
- ISIN
- FR0010425595
- LEI
- 5493000KKX5VQ37Q2W83
- P/E
- kahjum
- FCF
- −41.8 mln USD
- Võlg
- ?
- Kasum ja FCF — 12 kuu jooksul kuni 31.12.2025 (ettevõtte viimane raport).
- NAV
Kirjeldus
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| B Group, Inc. | 4.55% | 3.28 mln | 2026-06-30 |
| Long Focus Capital Manag… | 3.8% | 2.74 mln | 2026-06-30 |
| UBS AM, a distinct busin… | 3.67% | 2.64 mln | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.33% | 235 696 | 2026-08-31 |
| Nomura Asset Management… | 0.31% | 226 875 | 2026-06-30 |
| Delaware Group Equity Fu… | 0.31% | 226 875 | 2026-06-30 |
| Blackrock Inc. | 0.31% | 225 444 | 2026-06-30 |
| Morgan Stanley | 0.12% | 85 455 | 2026-06-30 |
| LPL Financial LLC | 0.12% | 84 415 | 2026-06-30 |
| Susquehanna Internationa… | 0.07% | 50 453 | 2026-06-30 |
| BNP Paribas Financial Ma… | 0.06% | 40 100 | 2026-06-30 |
| UBS Group AG | 0.05% | 33 926 | 2026-06-30 |
| Fidelity Concord Street… | 0% | 1 949 | 2026-07-31 |
Logi Sisse Google